We are live on ! Find out more

Galectin Therapeutics

GALT

Market cap $376M

3.73 USD

-0.11

2.86%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

4.00

+0.27

7.24%

1 day

-2.86%

5 days

-9.69%

1 month

6.27%

3 months

42.37%

6 months

17.3%

Year to date

-7.9%

1 year

-17.11%

5 years

0%

10 years

118.13%

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 9

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 50%

Negative 25%

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C.

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

20 stocks likely to lose money even if the bull market continues

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

20 stocks likely to lose money even if the bull market continues

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga.

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Top 3 Health Care Stocks That May Keep You Up At Night In June

As of June 30, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Keep You Up At Night In June

Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside

Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces uncertainty and shortens timelines. GALT's valuation reflects skepticism about execution, financing risk, and commercial viability, but successful Phase 3 results could trigger a significant re-rating.

Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside

Zacks Investment Research

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis

NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27–30, 2026, in Barcelona, Spain.

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026.

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

See News Rankings

Price charts implemented using Lightweight Charts™